A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.

Ezio Zanon,Samantha Pasca,Gianluca Sottilotta,Angelo C Molinari,Antonietta Ferretti,Patrizia Di Gregorio,Berardino Pollio,Michele Pizzuti,Lucia Dora Notarangelo,Chiara Biasoli,Piergiorgio Cojutti,Federico Pea,Paolo Simioni,Flora Peyvandi

Blood transfusion = Trasfusione del sangue（2022）

引用 0|浏览7

暂无评分

摘要

Efficacy and safety of rFXIII were proven in all patients. The dosage and infusion timing for the treated patients sometimes differed to those reported in the MENTOR pivotal studies, thus underlying the importance of tailored management in a real-world scenario.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要